MedTrace Logo

Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

NCT01042119 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2010-06-24

No results posted yet for this study

Summary

The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.

The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.

Conditions

  • Overactive Bladder Syndrome

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • David A Scheiner, MD · University Hospital of Zurich, Clinic for Gynaecology

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01042119 on ClinicalTrials.gov